Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) reported second quarter 2026 revenue of $5.2 million, up 35% year over year, with first-half 2026 revenue of $10.3 million, up 51%. Growth was driven by higher service revenue, mainly from sleep testing and treatment services in Nevada operations.
Gross profit rose to $3.0 million in Q2 and $6.0 million for the first half, with gross margins improving to 57% and 58%, respectively. Operating expenses increased to $7.8 million in Q2 and $17.5 million year-to-date, reflecting the SCN acquisition and new treatment centers. Vivos recorded a Q2 net loss of $5.5 million and a first-half net loss of $13.3 million. As of June 30, 2026, cash and equivalents were $1.8 million, and stockholders’ equity showed a deficit of $3.8 million. Management highlighted rising patient referrals, growing pediatric and insomnia programs, and progress toward partnerships with multi-center cardiology groups in Florida and Arizona.
Positive
- Q2 2026 revenue up 35% YoY to $5.2 million
- First-half 2026 revenue up 51% YoY to $10.3 million
- Service revenue Q2 2026 $3.8 million vs. $1.9 million in 2025
- Gross margin improved to 57% in Q2 2026 from 55% in Q2 2025
- First-half gross margin increased to 58% from 53% year over year
- Management reports significantly higher physician referrals and pediatric program volumes since early Q2 2026
Negative
- Q2 2026 net loss widened to $5.5 million from $5.0 million
- First-half 2026 net loss increased to $13.3 million from $8.9 million
- Operating expenses Q2 2026 rose 12% YoY to $7.8 million
- First-half operating expenses increased to $17.5 million from $12.4 million
- Product revenue Q2 2026 declined to $1.4 million from $1.9 million
- Stockholders’ equity deficit deepened to $3.8 million from $1.5 million at year-end 2025
- Cash and equivalents decreased to $1.8 million from $2.0 million at December 31, 2025
News Explained
June 30 records show 14.5 million common shares versus 9.3 million at year-end, reducing existing holders’ ownership percentage absent offsets.
Vivos Therapeutics reported unaudited second-quarter results for the period ended
In plain terms, additional shares increase the total share count and dilute an existing holder’s ownership percentage; the disclosure also lists
Cash and equivalents were
The
Sources and calculations
- Vivos Therapeutics Q2 2026 financial results and operational update (2026-08-14)
- Dilution definition (2026-07-17)
- Vivos Therapeutics Q2 2026 fundamentals record (2026Q2)
- Vivos Therapeutics Form 10-Q (2026-08-14)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $1,774,000 / ($3,148,000 / 90) = [object Object]
Market reaction after 2Q26 earnings report: VVOS -3.35%
Following this news, VVOS has declined 3.35%, reflecting a moderate negative market reaction. Argus tracked a trough of -1.8% from its starting point during tracking. Our momentum scanner has triggered 32 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.33. Trading volume is exceptionally heavy at 6.8x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 20 | Q1 earnings | Negative | -0.9% | Revenue grew, but net loss widened and cash remained limited |
| Apr 15 | FY2025 earnings | Negative | -25.9% | Revenue increased, while operating loss widened on higher expenses |
| Aug 19 | Q2 earnings | Negative | -3.3% | Revenue declined despite strategic transition and acquisition-related progress |
| May 15 | Q1 earnings | Negative | -17.0% | Revenue decreased and net loss increased modestly year over year |
| Mar 31 | FY2024 earnings | Positive | -7.7% | Revenue increased, margins held, and operating loss decreased materially |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across five tag-specific earnings events, the stock recorded negative reactions averaging -10.94%, with four aligned outcomes and one divergence.
Key Terms
obstructive sleep apnea medical
510(k) regulatory
form 10-q regulatory
non-controlling interest financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Quarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of
highly effective OSA treatments
Management to Host Conference Call today at 5:00 pm ET
LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, today reported financial results and operating highlights for the three and six months ended June 30, 2026.
Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “The second quarter of 2026 represented a watershed moment in the history of Vivos as we continued to lay the foundation for potential significant revenue enhancement and growth for the remainder of 2026 and beyond. In that regard, we expanded our physical facilities and production capacity, increased our total provider count, initiated our AI-enabled software conversion at SCN, and established new lines of referrals and service initiatives.”
Mr. Huntsman continued, “Here in the third quarter, the concrete actions taken during Q2 are already yielding significant gains in terms of both patient volume and revenue growth. For example, since the beginning of the second quarter we have seen weekly physician referral volumes into our Nevada SAMC treatment centers rise significantly compared to the first quarter, while patient referrals generated by our insomnia / EEG program, EEG testing, and overall program revenue generated all increased significantly compared to the first quarter. Significant patient and revenue gains have also begun to emerge from our pediatric program across multiple markets as well. Finally, we have continued to make significant strides towards finalization of our pending partnerships and affiliations with large multi-center cardiology groups in key Florida and Arizona markets.”
Second Quarter 2026 Financial and Operating Summary
- Revenue increased
35% and51% for the three and six months ended June 30, 2026 over the same periods in 2025. - Revenue was
$5.2 million for the second quarter of 2026 and$10.3 million for the six months ended June 30, 2026, compared to$3.8 million and$6.8 million for the three and six months ended June 30, 2025. The increase in total revenue in the second quarter of 2026 was driven by service revenue, which was primarily attributable to sleep testing and resulting treatment services in our Nevada operations; - Gross profit was
$3.0 million for the second quarter of 2026 and$6.0 million for the six months ended June 30, 2026, compared to$2.1 million and$3.6 million for the comparable periods in 2025, the increases due to stronger revenue and a smaller increase in cost of sales; - Gross margin increased to
57% in the second quarter of 2026 from55% in the second quarter of 2025, due to the increase in revenue. For the six months ended June 30, 2026, gross margin was58% compared to53% in the same period in 2025, due to increases in revenue and reduced increases in cost of sales; - Operating expenses for the second quarter ended June 30, 2026 were
$7.8 million , a12% increase compared to$7.0 million in the same period a year ago, reflecting increased salaries and wages from the SCN acquisition and opening Vivos treatment centers. For the six months ended June 30, 2026, operating expenses were$17.5 million versus$12.4 million in the same period in 2025. - The second quarter 2025 operating loss was
$4.9 million , flat compared to$4.9 million in the second quarter of 2025 and increased to$11.4 million for the six months ending June 30, 2026 from$8.8 million for the six months ended June 30, 2025. - At June 30, 2026, cash and cash equivalents were
$1.8 million and stockholders’ equity was a deficit of$3.8 million , compared to cash and equivalents of$2.0 million and stockholders’ equity deficit of$1.5 million respectively, as of December 31, 2025.
Investor Call and 10-Q Filing
Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos’ strategic initiatives and their anticipated effect on near-term revenue growth and cash burn.
To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1174558. The replay will be available until Friday, August 28, 2026.
A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investors/. An online archive of the webcast will be available at Vivos’ website for 30 days following the call.
In addition, further information on Vivos’ financial results is included on the attached unaudited condensed consolidated balance sheets and statements of operations, and additional comments around Vivos’ financial performance are provided in the Vivos’ Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, which has been filed with the Securities and Exchange Commission (“SEC”). The full 10-Q report will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investors/.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children.
OSA and insomnia affect over 1 Billion adults aged 30-69 years old worldwide, yet
Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward‑Looking Statements
This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements.
These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Actual results (including the actual benefits of the Company’s new model described herein and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, a deficiency in its stockholders’ equity; (v) market and other conditions, and (vi) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov.
Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any such statement is based.
Vivos Investor Relations Contact:
Jennifer Hauser, Executive Assistant to the CEO
jhauser@vivoslife.com
720-927-3125
| VIVOS THERAPEUTICS INC. Unaudited Condensed Consolidated Statements of Operations (In Thousands, Except Per Share Amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | ||||||||||||||||
| Product revenue | $ | 1,355 | $ | 1,885 | $ | 2,795 | $ | 3,698 | ||||||||
| Service revenue | 3,798 | 1,935 | 7,499 | 3,137 | ||||||||||||
| Total revenue | 5,153 | 3,820 | 10,294 | 6,835 | ||||||||||||
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 2,200 | 1,710 | 4,282 | 3,219 | ||||||||||||
| Gross profit | 2,953 | 2,110 | 6,012 | 3,616 | ||||||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 7,113 | 6,409 | 16,083 | 11,298 | ||||||||||||
| Sales and marketing | 155 | 260 | 404 | 615 | ||||||||||||
| Depreciation and amortization | 510 | 306 | 965 | 483 | ||||||||||||
| Total operating expenses | 7,778 | 6,975 | 17,452 | 12,396 | ||||||||||||
| Operating loss | (4,825 | ) | (4,865 | ) | (11,440 | ) | (8,780 | ) | ||||||||
| Non-operating income (expense) | ||||||||||||||||
| Other expense | (1,050 | ) | (163 | ) | (2,218 | ) | (170 | ) | ||||||||
| Other income | 352 | 15 | 384 | 73 | ||||||||||||
| Loss before income taxes | (5,523 | ) | (5,013 | ) | (13,274 | ) | (8,877 | ) | ||||||||
| Net loss | $ | (5,523 | ) | $ | (5,013 | ) | $ | (13,274 | ) | $ | (8,877 | ) | ||||
| Net loss attributable to non-controlling interest | (42 | ) | - | (111 | ) | - | ||||||||||
| Net loss attributable to stockholders | $ | (5,481 | ) | $ | (5,013 | ) | $ | (13,163 | ) | $ | (8,877 | ) | ||||
| Net loss per share (basic and diluted) | $ | (0.31 | ) | $ | (0.55 | ) | $ | (0.81 | ) | $ | (1.00 | ) | ||||
| Weighted average number of shares of Common Stock outstanding (basic and diluted) | 17,681,945 | 9,087,202 | 16,166,450 | 8,842,604 | ||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| VIVOS THERAPEUTICS INC. Unaudited Condensed Consolidated Balance Sheets (In Thousands, Except Per Share Amounts) | |||||||||
| June 30, 2026 | December 31, 2025 | ||||||||
| Current assets | |||||||||
| Cash and cash equivalents | $ | 1,774 | $ | 2,029 | |||||
| Accounts receivable, net of allowance of | 1,438 | 1,581 | |||||||
| Prepaid expenses and other current assets | 1,001 | 774 | |||||||
| Total current assets | 4,213 | 4,384 | |||||||
| Long-term assets | |||||||||
| Goodwill | 8,572 | 8,572 | |||||||
| Property and equipment, net | 3,640 | 3,757 | |||||||
| Operating lease right-of-use asset | 3,809 | 4,166 | |||||||
| Intangible assets, net | 3,638 | 4,045 | |||||||
| Deposits and other | 272 | 228 | |||||||
| Total assets | $ | 24,144 | $ | 25,152 | |||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT) | |||||||||
| Current liabilities | |||||||||
| Accounts payable | $ | 2,946 | $ | 1,679 | |||||
| Accrued expenses | 7,042 | 5,988 | |||||||
| Contract liabilities | 583 | 479 | |||||||
| Current portion of operating lease liability | 790 | 672 | |||||||
| Current portion of financing lease liability | 56 | 55 | |||||||
| Current portion of debt | 7,772 | 8,353 | |||||||
| Other current liabilities | 1,200 | 850 | |||||||
| Total current liabilities | 20,389 | 18,076 | |||||||
| Long-term liabilities | |||||||||
| Employee retention credit liability | 2,904 | 2,904 | |||||||
| Operating lease liability, net of current portion | 3,438 | 3,840 | |||||||
| Financing lease liability, net of current portion | 83 | 113 | |||||||
| Debt, net of current portion | 366 | 469 | |||||||
| Other liabilities | 950 | 1,300 | |||||||
| Total liabilities | 28,130 | 26,702 | |||||||
| Commitments and contingencies | - | - | |||||||
| Stockholders’ equity/(deficit) | |||||||||
| Preferred Stock, | $ | - | $ | - | |||||
| Preferred Stock – additional paid in capital | 1,105 | - | |||||||
| Common Stock, | 1 | 1 | |||||||
| Additional paid-in capital | 133,599 | 123,866 | |||||||
| Accumulated deficit | (138,520 | ) | (125,357 | ) | |||||
| Total stockholders’ equity/(deficit) | (3,815 | ) | (1,490 | ) | |||||
| Non-controlling interest | (171 | ) | (60 | ) | |||||
| Total equity/(deficit) | (3,986 | ) | (1,550 | ) | |||||
| Total liabilities and equity/(deficit) | $ | 24,144 | $ | 25,152 | |||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
